Ovarian Cancer Health Center

Font Size
A
A
A

Hormone Therapy Raises Ovarian Cancer Risk

Study Shows an Increase in Risk for Estrogen-Only or Estrogen-Plus-Progestin Therapy
(continued)

Second Opinion

"It's a well done study," says Andrew Li, MD, a gynecologic oncologist at Cedars-Sinai Medical Center, Los Angeles, who reviewed the study for WebMD. "Their findings are in line with what other people report," says Li, who is also an assistant clinical professor of obstetrics and gynecology at the University California Los Angeles' David Geffen School of Medicine.

Like most research, the study has limitations that may have affected the results, Li says, and the authors also acknowledge this. Among the limitations are that the researchers didn't adjust for age at menopause or use of birth control pills; birth control pill use and early natural menopause both reduce ovarian cancer risk.

The main contribution of the new study is to look at large numbers of women who took different types of hormone therapy and determine which type or types carry risk, says Shelley Tworoger, PhD, an assistant professor of medicine and epidemiology at the Harvard School of Medicine and School of Public Health, who has also published her research on hormone therapy and ovarian cancer risk. "The real contribution [of the new study] is that the combined regimen also increases the risk of ovarian cancer," she says.  In her research, Tworoger found that estrogen-only therapy boosted risk and a suggestion of an increased risk with estrogen and progestin therapy.

The new research basically confirms what has been shown in previous studies, says Corrado Altomare, MD, senior director of global medical affairs for Wyeth Pharmaceuticals in Collegeville, Pa. "This finding doesn't really change what we know," he tells WebMD. "We actually have a warning in our label about ovarian cancer."

Wyeth's label summarizes the risks found for ovarian cancer with hormone use, using information from various studies.

The best advice for women? "If a woman has a special predisposition for ovarian cancer, she should consider not taking hormones," Morch says. Past users, she says, can be reassured that their risk declines to that of never users after being off the therapy for two years.

Even with the link to ovarian cancer, Morch says, she is not saying hormone therapy should never be used. "Hormones may still have a therapeutic place in women with severe perimenopausal symptoms, and among women going into premature menopause," she says.

Women should talk to their doctor about hormone use, Li says, so the decision can be based on individual risk factors and medical history.

1 | 2

cancer newsletter

An estimated 20K women are diagnosed with ovarian cancer each year. Get the information you need to manage your cancer from the health resource you can trust.

webMD Video

Show or hide information about video: Cancer and Exercise   Cancer and Exercise

Resting to conserve energy may not be the best remedy for fatigue during radiation therapy.

Watch Video: Cancer and Exercise (opens in a new window)

Show or hide information about video: Gaming Technology and Cancer   Gaming Technology and Cancer

Show or hide information about video: Cupping for Cancer   Cupping for Cancer

Show or hide information about video: Cancer Treatment Timing   Cancer Treatment Timing

Show or hide information about video: Ovarian Cancer Drug   Ovarian Cancer Drug

Advertise on Fox News Channel, FOXNews.com and FOX News Radio Jobs at FOX News Channel. Internships at FOX News Channel (now accepting Fall interns).
Terms of use. Privacy Statement. For FOXNews.com comments write to foxnewsonline@foxnews.com; For FOX News Channel comments write to comments@foxnews.com
© Associated Press. All rights reserved.
SMARTMONEY ® © 2006 SmartMoney. SmartMoney is a joint publishing venture of Dow Jones & Company, Inc. and Hearst SM Partnership. All Rights Reserved.
All quotes delayed by 20 minutes. Delayed quotes provided by ComStock.
Historical prices and fundamental data provided by Hemscott, Inc.
Mutual fund data provided by Lipper. Mutual Fund NAVs are as of previous day's close.
Earnings estimates provided by Zacks Investment Research.
Upgrades and downgrades provided by Briefing.com.
This material may not be published, broadcast, rewritten, or redistributed. © 2006 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.
About WebMD|Terms of Use|Privacy Policy|Sponsor Policy|Site Map|Link to Us|Careers|